In this issue:
- Mortality trends in IPF in Europe: 2013–2018
- Nerandomilast for IPF
- Bexotegrast for IPF
- Pirfenidone and lung cancer risk in IPF
- Pirfenidone in post-COVID-19 pulmonary fibrosis
- Sarcoidosis treatment patterns in the US: 2016–2022
- First-line prednisone or methotrexate for pulmonary sarcoidosis
- AI evaluation of lung function for ILD diagnosis
- Pulmonary sarcoidosis: differences in lung function change over time
- Tofacitinib vs. CNI in dermatomyositis-associated ILD
Please login below to download this issue (PDF)